Table 1 Questionnaire results (n = 21 centres)
Question | Yes n (%) |
|---|---|
Do you have a clear written policy regarding the assessment and listing of patients with CF and NTM infection? | 6 (29) |
During assessment do you require screening for NTM? | 21 (100) |
Do you require molecular identification of NTM species? | 16 (76) |
Do you regard current infection with MAC an absolute contraindication? | 1 (5) |
Do you regard current infection with M. abscessus complex as an absolute contraindication? | 4 (19) |
Do you regard persisting MAC or M. abscessus complex infection despite optimal therapy as an absolute contraindication? | 12 (57) |
Would you regard a patient with persisting M. abscessus complex and another relative contraindication as together representing an absolute contraindication? | 16 (76) |
Do you require specific NTM treatment to be undertaken before listing? | 18 (86) |
At time of listing is a treatment cocktail decided on for use peri-transplant? | 20 (95) |
Are patients segregated on the basis of NTM status pre-transplant? | 13 (62) |
Are patients segregated post-transplant on the basis of NTM status? | 10 (48) |